Global Gastro Esophageal Reflux Disease Drug and Devices Market Size By Type (Medigus Ultrasonic Surgical Endostapler, LINX Management System), By Application (Hospitals, Clinics), By Region, And Segm...

The Global Gastro Esophageal Reflux Disease (GERD) Drug and Devices Market was valued at USD 8.6 billion in 2023 and is projected to reach USD 13.9 billion by 2031, growing at a CAGR of 6.2% during the forecast period. GERD is a chronic condition where stomach acid flows back into the esophagus, causing symptoms such as heartburn and regurgitation. The rising prevalence of GERD globally, particularly due to lifestyle changes, obesity, aging populations, and dietary habits, is driving market growth. Innovations in drug formulations and the increasing adoption of minimally invasive procedures and diagnostic devices are further enhancing market expansion.

Drivers:

Rising Prevalence of GERD:

The increasing number of GERD cases worldwide—fueled by unhealthy dietary habits, sedentary lifestyles, obesity, and stress—has significantly boosted demand for both pharmaceutical and device-based treatments.

Technological Advancements in Diagnostic Devices:

The market is witnessing rapid innovation in diagnostic tools, such as pH monitoring systems, esophageal manometry, and endoscopy systems, which facilitate early and accurate diagnosis, improving treatment outcomes.

Surge in Minimally Invasive Procedures:

Endoscopic therapies and minimally invasive surgeries are gaining popularity due to quicker recovery, reduced side effects, and high success rates, making them attractive alternatives to long-term medication.

Restraints:

Adverse Effects of Long-term Medication:

Prolonged use of proton pump inhibitors (PPIs) and other GERD medications can lead to side effects like nutrient malabsorption and increased risk of kidney disease, reducing patient compliance and hindering market growth.

High Cost of Surgical and Diagnostic Devices:

Advanced GERD diagnostic and surgical devices involve significant costs, posing affordability issues, especially in low- and middle-income countries.

Opportunity:

Emerging Markets and Untapped Populations:

With improving healthcare infrastructure and growing awareness, emerging economies present significant growth opportunities for GERD treatments, both in terms of drugs and devices.

Personalized Medicine and Combination Therapies:

Innovations in personalized medicine, including tailored drug regimens and the combination of drug-device therapies, are expected to improve patient outcomes and open new revenue streams for market players.

Market by System Type Insights:

In 2023, the drug segment dominated the market, led by proton pump inhibitors and H2-receptor antagonists. These drugs are the first line of treatment and widely prescribed. However, the devices segment, particularly implantable devices like LINX and transoral incisionless fundoplication (TIF) systems, is expected to grow at the fastest rate, owing to increasing adoption of minimally invasive treatments.

Market by End-use Insights:

The hospital segment was the largest revenue generator in 2023 due to high patient inflow for diagnosis and treatment procedures. The ambulatory surgical centers (ASCs) segment is projected to grow rapidly as they provide cost-effective, outpatient solutions, especially for device-based therapies.

Market by Regional Insights:

North America accounted for the largest share of the GERD drug and devices market in 2023, driven by a high incidence rate, advanced healthcare systems, and robust reimbursement policies. Asia-Pacific is expected to witness the highest CAGR during the forecast period due to increasing healthcare spending, rising awareness, and a large geriatric population base.

Competitive Scenario:

Leading players in the market include AstraZeneca plc, Johnson & Johnson Services, Inc., Medtronic plc, Takeda Pharmaceutical Company Limited, Ironwood Pharmaceuticals, Inc., EndoGastric Solutions, Inc., and Bayer AG. These companies are investing in product innovation, expanding geographic reach, and engaging in strategic partnerships.

Recent Developments:

2023: Medtronic introduced an upgraded LINX device with improved biocompatibility and feedback mechanisms.

2024: Takeda received FDA approval for a next-gen proton pump inhibitor with enhanced absorption and reduced side effects.

2025: EndoGastric Solutions expanded its TIF technology platform across key Asia-Pacific markets through new distributor partnerships.

Scope of Work – Global Gastro Esophageal Reflux Disease Drug and Devices Market

Report Metric Details

Market Size (2023) USD 8.6 billion

Projected Market Size (2031) USD 13.9 billion

CAGR (2023–2031) 6.2%

Market Segments By System Type (Drugs, Devices), By End-use (Hospitals, ASCs, Others)

Growth Drivers Rising GERD prevalence, tech innovations in diagnosis & treatment

Opportunities Emerging markets, combination therapies, personalized medicine

Key Market Developments:

AstraZeneca launched a co-packaged therapy combining PPIs and antacids to address refractory GERD cases (2023).

Johnson & Johnson expanded its surgical device portfolio by acquiring a startup focused on endoscopic GERD treatment (2024).

Ironwood Pharmaceuticals initiated Phase III trials for a novel motility-enhancing drug targeting GERD with gastroparesis overlap (2025).

FAQs:

1) What is the current market size of the Global Gastro Esophageal Reflux Disease Drug and Devices Market?

The market was valued at USD 8.6 billion in 2023.

2) What is the major growth driver of the Global Gastro Esophageal Reflux Disease Drug and Devices Market?

The rising global prevalence of GERD, coupled with technological advancements in treatment and diagnosis, is a key growth driver.

3) Which is the largest region during the forecast period in the Global Gastro Esophageal Reflux Disease Drug and Devices Market?

North America is expected to remain the largest region through the forecast period.

4) Which segment accounted for the largest market share in the Global Gastro Esophageal Reflux Disease Drug and Devices Market?

The drug segment held the largest market share in 2023, particularly proton pump inhibitors.

5) Who are the key market players in the Global Gastro Esophageal Reflux Disease Drug and Devices Market?

Major players include AstraZeneca, Johnson & Johnson, Medtronic, Takeda, Ironwood Pharmaceuticals, EndoGastric Solutions, and Bayer.